Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

PubWeight™: 1.07‹?› | Rank: Top 10%

🔗 View Article (PMID 16153753)

Published in Vaccine on July 26, 2005

Authors

C M Carpenter1, E R Hall, R Randall, R McKenzie, F Cassels, N Diaz, N Thomas, P Bedford, M Darsley, C Gewert, C Howard, R B Sack, D A Sack, H S Chang, G Gomes, A L Bourgeois

Author Affiliations

1: Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N. Broadway, HH, Rm 205, Baltimore, MD 21205, USA.

Articles citing this

The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol (2008) 6.02

Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PLoS One (2015) 1.43

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol (2012) 1.14

Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc (2013) 0.97

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol (2011) 0.97

Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun (2006) 0.97

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli. PLoS One (2016) 0.79

Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea. Clin Vaccine Immunol (2016) 0.78

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens. Vaccine (2011) 0.77

Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Clin Vaccine Immunol (2016) 0.76

The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. Front Immunol (2017) 0.75

Articles by these authors

Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect Immun (1975) 13.58

Orchestrated transcription of key pathways in Arabidopsis by the circadian clock. Science (2000) 12.35

Human diarrheal disease caused by enterotoxigenic Escherichia coli. Annu Rev Microbiol (1975) 9.01

Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med (1976) 7.57

Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis (1971) 7.10

Human gene mutation database-a biomedical information and research resource. Hum Mutat (2000) 6.87

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83

Matching using estimated propensity scores: relating theory to practice. Biometrics (1996) 6.73

Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress. N Engl J Med (1976) 6.52

Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal micrflora. J Clin Invest (1971) 6.23

Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet (1993) 5.48

Immunologic cross-reactions of enterotoxins from Escherichia coli and Vibrio cholerae. J Infect Dis (1973) 5.46

Enzyme-linked immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1977) 5.17

Special Escherichia coli serotypes among enterotoxigenic strains from diarrhoea in adults and children. Med Microbiol Immunol (1976) 4.95

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72

Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry (1984) 4.72

Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet (1990) 4.62

Practice guidelines for the management of infectious diarrhea. Clin Infect Dis (2001) 4.49

Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13

Experimental canine cholera. I. Development of the model. J Infect Dis (1969) 4.02

Multiple transcription-factor genes are early targets of phytochrome A signaling. Proc Natl Acad Sci U S A (2001) 3.91

X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nat Genet (1996) 3.90

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol (1998) 3.77

Attachment of Vibrio cholerae serogroup O1 to zooplankton and phytoplankton of Bangladesh waters. Appl Environ Microbiol (1990) 3.73

Site and characteristics of electrolyte loss and effect of intraluminal glucose in experimental canine cholera. J Clin Invest (1968) 3.72

Simple adult rabbit model for Vibrio cholerae and enterotoxigenic Escherichia coli diarrhea. Infect Immun (1981) 3.69

Cytotoxic enterotoxin produced by Aeromonas hydrophila: relationship of toxigenic isolates to diarrheal disease. Infect Immun (1979) 3.65

Enterotoxigenic Escherichia coli isolated from food. J Infect Dis (1977) 3.52

Cholera control. Lancet (1994) 3.38

Enterotoxigenic Escherichia coli and Reovirus-like agent in rural Bangladesh. Lancet (1976) 3.38

Laboratory investigation of diarrhea in travelers to Mexico: evaluation of methods for detecting enterotoxigenic Echerichia coli. J Clin Microbiol (1976) 3.34

Microtiter ganglioside enzyme-linked immunosorbent assay for vibrio and Escherichia coli heat-labile enterotoxins and antitoxin. J Clin Microbiol (1980) 3.30

Diarrhoea associated with heat-stable enterotoxin-producing strains of Escherichia coli. Lancet (1975) 3.27

Oral rehydration therapy of infantile diarrhea: a controlled study of well-nourished children hospitalized in the United States and Panama. N Engl J Med (1982) 3.24

Diarrheal disease during Operation Desert Shield. N Engl J Med (1991) 3.22

Detection of Vibrio cholerae O1 in the aquatic environment by fluorescent-monoclonal antibody and culture methods. Appl Environ Microbiol (1990) 3.21

Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol (1999) 3.11

Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09

Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07

A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med (1993) 3.07

Progressive changes of Vibrio serotypes in germ-free mice infected with Vibrio cholerae. J Bacteriol (1969) 3.01

Antitoxin responses to infections with enterotoxigenic Escherichia coli. J Infect Dis (1974) 2.88

Prophylactic doxycycline for travelers' diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med (1978) 2.86

Field trial of oral cholera vaccines in Bangladesh. Lancet (1986) 2.85

Epidemic diarrhea at Crater Lake from enterotoxigenic Escherichia coli. A large waterborne outbreak. Ann Intern Med (1977) 2.80

Enterotoxigenic Escherichia-coli-associated diarrheal disease in Apache children. N Engl J Med (1975) 2.74

Microtiter solid-phase radioimmunoassay for detection of Escherichia coli heat-labile enterotoxin. Infect Immun (1977) 2.72

Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol (2000) 2.69

Vibriocidal and agglutinating antibody patterns in cholera patients. J Infect Dis (1966) 2.67

Parental refusal to have children immunised: extent and reasons. BMJ (1995) 2.61

El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect (2009) 2.60

Isolation of enterotoxigenic Bacteroides fragilis from humans with diarrhea. J Clin Microbiol (1987) 2.58

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis (1988) 2.57

Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56

Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. Int J Epidemiol (1991) 2.56

Interpreting hospital mortality data. The role of clinical risk adjustment. JAMA (1989) 2.53

Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49

Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am (1986) 2.49

Human colonic epithelial cells, HT29/C1, treated with crude Bacteroides fragilis enterotoxin dramatically alter their morphology. Infect Immun (1992) 2.41

Genotypes associated with virulence in environmental isolates of Vibrio cholerae. Appl Environ Microbiol (2001) 2.41

Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA (2001) 2.38

Neuronal correlate of pictorial short-term memory in the primate temporal cortex. Nature (1988) 2.37

Laboratory and bedside evaluation of portable glucose meters. Am J Clin Pathol (1995) 2.35

Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Br Med J (Clin Res Ed) (1986) 2.33

Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet (1987) 2.32

Primary prevention of childhood lead exposure: A randomized trial of dust control. Pediatrics (1999) 2.32

D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28

Replacement of water and electrolyte losses in cholera by an oral glucose-electrolyte solution. Ann Intern Med (1969) 2.28

An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23

Tissue-culture assay of antibodies to heat-liable Escherichia coli enterotoxins. N Engl J Med (1974) 2.20

Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. J Infect Dis (2001) 2.20

In vitro differentiation of Trypanosoma cruzi under chemically defined conditions. Mol Biochem Parasitol (1985) 2.20

Predicting hospital-associated mortality for Medicare patients. A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure. JAMA (1989) 2.19

Race-related socialization, motivation, and academic achievement: a study of black youths in three-generation families. J Am Acad Child Psychiatry (1985) 2.19

Enterotoxigenic Escherichia coli: identification and characterization. J Infect Dis (1980) 2.16

Mutation in the peb1A locus of Campylobacter jejuni reduces interactions with epithelial cells and intestinal colonization of mice. Infect Immun (1998) 2.14

Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13

Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. J Infect Dis (1977) 2.13

Small bowel morphology in experimental canine cholera. A light and electron microscopic study. Lab Invest (1970) 2.12

Production, characterization, and application of monoclonal antibodies to Vibrio cholerae O139 synonym Bengal. Clin Diagn Lab Immunol (1994) 2.07

The aquatic flora and fauna as reservoirs of Vibrio cholerae: a review. J Diarrhoeal Dis Res (1994) 2.04

Enterotoxigenic Escherichia coli isolated from patients at a hospital in Dacca. J Infect Dis (1977) 2.03

FATAL ENCEPHALITIS IN MAN DUE TO THE VENEZUELAN VIRUS OF EQUINE ENCEPHALOMYELITIS IN TRINIDAD. Science (1944) 2.02

Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun (1997) 2.01

Relationship between enterotoxin production and serotype in enterotoxigenic Escherichia coli. Infect Immun (1979) 2.01

Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet (1995) 1.95

Cholera epidemics in Bangladesh: 1985-1991. J Diarrhoeal Dis Res (1992) 1.92

Enteropathogens associated with acute and persistent diarrhea in Bangladeshi children less than 5 years of age. J Infect Dis (1992) 1.91